Corcept Therapeutics Inc

Corcept Therapeutics Inc

CORT

Market Cap$7.66B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Corcept Therapeutics IncCorcept Therapeutics Inc56.6-19%11.4-
$140.00

Target Price by Analysts

105.4% upsideCorcept Therapeutics Target Price DetailsTarget Price
$204.05

Current Fair Value

199.4% upside

Undervalued by 199.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$7.66 Billion
Enterprise Value$7.60 Billion
Dividend Yield$0 (0%)
Earnings per Share$1.35
Beta0.18
Outstanding Shares104,106,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio56.63
PEG-210.36
Price to Sales11.36
Price to Book Ratio11.36
Enterprise Value to Revenue11.08
Enterprise Value to EBIT68.51
Enterprise Value to Net Income57
Total Debt to Enterprise0
Debt to Equity0.03

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Corcept Therapeutics Inc

CEO: Joseph Belanoff

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...